Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study by Solbu, Marit D. et al.
954  |    J Clin Hypertens. 2021;23:954–962.wileyonlinelibrary.com/journal/jch
Received: 9 October 2020  | Revised: 16 January 2021  | Accepted: 27 January 2021
DOI: 10.1111/jch.14214  
O R I G I N A L  P A P E R
Kidney function and markers of renal damage after renal 
denervation. Does method of measurement matter? The 
Reshape CV- Risk Study
Marit D. Solbu MD, PhD1,2  |   Atena Miroslawska MD3,4 |   Jon V. Norvik MD, PhD1,2 |   
Bjørn O. Eriksen MD, PhD1,2 |   Terje K. Steigen MD, PhD3,4
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC
1Section of Nephrology, University 
Hospital of North Norway, Tromsø, 
Norway
2Metabolic and Renal Research Group, UiT 
The Arctic University of Norway, Tromsø, 
Norway
3Clinical Cardiovascular Research Group, 
UiT The Arctic University of Norway, 
Tromsø, Norway
4Department of Cardiology, University 
Hospital of North Norway, Tromsø, 
Norway
Correspondence
Marit D. Solbu, Section of Nephrology, 
Division of Internal Medicine, University 




All authors are funded by Governmental 
Non- Profit Organizations in Norway, 
including The North Norwegian Regional 
Health Authorities, the University 
Hospital of North Norway and UiT The 
Arctic University of Norway. We also 
received an unrestricted grant from the 
Medtronic Company.
Abstract
Data suggest that renal denervation (RDN) in treatment- resistant hypertension 
(TRHT) is safe in terms of renal function. However, most studies report kidney func-
tion as creatinine- based estimated glomerular filtration rate (eGFR), which may be 
biased by non- renal factors. Damage markers other than albuminuria have never been 
evaluated after RDN. In this non- randomized RDN trial, we studied changes in kidney 
function, assessed as measured GFR (mGFR) and various GFR estimates, six months 
and two years after RDN. We also examined changes in albuminuria and a biomarker 
of tubular dysfunction. Adult non- diabetic patients with TRHT and eGFR ≥45 ml/
min/1.73 m2 were recruited from hypertension clinics. Before bilateral RDN, mGFR 
was measured by iohexol clearance. We estimated eGFR from serum creatinine and 
cystatin C (eGFRcrea, eGFRcys, and eGFRcreacys), and albumin- creatinine ratio (ACR) and 
N- acetyl- β- D- glucosaminidase (NAG)- creatinine ratio (NAG- CR) were measured in 
spot urines. All measurements were repeated after six and twenty- four months.
Twenty patients, mean age 54 (±9) years and baseline mGFR 83 (±20) ml/min/1.73 
m2 underwent RDN. After six months, mGFR fell, eGFRcrea remained unchanged, 
whereas eGFRcys and eGFRcreacys increased. At 2 years’ follow- up, eGFRcreacys was 
significantly lower than at baseline. mGFR was 78 (±28) ml/min/1.73 m2. Change in 
ambulatory systolic BP predicted change in eGFRcrea. Urinary NAG- CR, but not ACR, 
increased during follow- up.
Different GFR assessments gave diverging results after RDN. Therefore, care 
should be taken to method when evaluating kidney function after RDN. Increases in 
a tubular dysfunction biomarker suggest that kidney damage may occur. Long- term 
renal follow- up is needed after RDN.
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1 | INTRODUC TION
According to the World Health Organization, hypertension (HT) is 
the largest single contributor to overall morbidity and mortality.1 
HT affects approximately 40% of the adult population and is the 
most important modifiable risk factor for cardiovascular disease 
(CVD), chronic kidney disease (CKD), and dementia.1,2 Treatment- 
resistant hypertension (TRHT) is defined as blood pressure (BP) 
levels remaining above the treatment goal despite the use of three 
antihypertensive drugs, including a diuretic, at optimal doses, and 
with confirmed adherence.3 The prevalence of TRHT is believed to 
be about 10% of treated hypertensive patients, and TRHT infers 
higher risk of CKD and premature CVD compared to controlled 
HT.4
TRHT is associated with increased sympathetic nervous system 
activity,5 especially in patients with obesity and the metabolic syn-
drome.6 The kidney is one of the main targets of increased sympa-
thetic activity, with both afferent and efferent renal sympathetic 
nerve fiber traffic being involved in the generation of systemic va-
soconstriction and sodium retention, resulting in HT and not infre-
quently TRHT.7 These mechanisms constitute the rationale for renal 
sympathetic denervation (RDN) as a treatment mode for TRHT.8 The 
first blinded, sham- controlled randomized controlled trial of RDN 
showed no significant benefit on 24- hour ambulatory systolic BP 
(SYMPLICITY HTN- 3),9 and consequentially, the enthusiasm for this 
interventional procedure fell abruptly. However, recent renewed in-
terest has risen for various invasive techniques, including RDN with 
new devices and new procedures, to modulate sympathetic nervous 
system activity in patients with TRHT.5,10- 12
Intensive BP lowering has been demonstrated to slow the 
rate of disease progression in patients with CKD,13 possibly also 
implying that BP lowering may prevent the development of CKD 
in the first place.3 However, all procedures directly affecting the 
renal arteries confer some risk of direct damage,14- 16 potentially 
leading to reduced kidney function or increased levels of renal 
damage biomarkers in the short or long term. Moreover, hemo-
dynamic changes due to rapid BP lowering may result in a tem-
porary decrease in the glomerular filtration rate (GFR). So far, 
studies have not revealed an accelerated kidney function decline 
rate after RDN,16- 19 and urinary albumin excretion (UAE) has been 
demonstrated to improve.20- 22 However, most studies have re-
ported kidney function as estimated GFR (eGFR) calculated from 
serum creatinine, cystatin C, or both,23 which may be biased by 
non- GFR factors such as body composition and inflammation.24 
This bias may be avoided using GFR measured by gold- standard 
methods, for example, iohexol clearance (mGFR).24 We are aware 
of only one study using mGFR to assess kidney function in an RDN 
setting.25 Changes in urinary biomarkers reflecting renal tubular 
dysfunction have to our knowledge never been studied in TRHT 
patients treated with RDN.
In the present non- randomized study of patients with TRHT, we 
assessed various markers of kidney dysfunction, including mGFR, 
eGFR, UAE, and N- acetyl- β- D- glucosaminidase (NAG), a urinary bio-
marker of proximal tubular dysfunction, before RDN and six months 
and two years after the treatment. We hypothesized a gradual im-
provement in all variables.
2  |  MATERIAL S AND METHODS
2.1  |  Study population
The study design has been published in detail previously.26 In short, 
patients aged 18 to 68 years with TRHT were recruited from HT 
specialist clinics in Norway. TRHT was defined as office systolic 
BP > 140 mm Hg despite regular intake of maximally tolerated doses 
of at least four antihypertensive drugs, including a diuretic. No 
changes in medication were allowed the last two weeks before enroll-
ment. In addition, daytime systolic BP > 135 mm Hg by ambulatory BP 
monitoring (ABPM), after investigator- witnessed intake of prescribed 
antihypertensive drugs from original packaging, was required for in-
clusion. Patients with eGFR ≤ 45 ml/min/1.73 m2 were excluded. The 
study was originally designed to assess changes in glucose metabo-
lism assessed by gold- standard method, that is, a hyperinsulinaemic- 
euglycaemic clamp with glucose tracer and labeled glucose infusion, 
and therefore, patients with diabetes at baseline were excluded. The 
protocol has the following ClinicalTrials.gov identifier: NCT01630928. 
The study was conducted in accordance with the protocol, as well as 
with applicable regulatory requirements and the ethical principles 
of the Declaration of Helsinki. All included patients gave their writ-
ten, informed consent, and The Regional Committee for Medical and 
Health Research Ethics and the Data Protection Officer at University 
Hospital of North Norway gave their approval (2011/1296/REK 
Nord).
2.2  |  Procedures
A detailed description of the procedures has been published.26 
Baseline data were collected between March 2013 and February 
2014. Procedures were repeated by the same research team, using 
identical procedures, at six months and two years after RDN.
After investigator- witnessed pill intake, patients were under 
observation by the nurse until a 24- hours ambulatory BP mea-
surement device (Schiller BR- 102 plus; SCHILLER- Reomed AG, 
Dietikon, Switzerland) had been connected and tested. BP read-
ings were taken every 20 min during daytime (0700 hours to 
2200 hours), and every 30 min during nighttime (2200 hours to 
0700 hours).
With the patient in a seated position, and after 5 minutes’ rest, 
office BP was measured at one- minute intervals with an automatic 
oscillometric device (Casmed 740; Infiniti Medical, Menlo Park, CA, 
USA). At baseline, BP was measured on both arms, and the arm with 
the higher BP was used for all subsequent readings. We used the 
mean of the second and third readings in the analyses. Controlled 
BP at follow- up was defined as office systolic BP < 140 mm Hg and 
diastolic BP < 90 mm Hg.
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Within four weeks after the baseline measurements, bilat-
eral RDN was performed using the SymplicityTM Catheter System 
(Medtronic, Mountain View, CA, USA) by one experienced interven-
tional cardiologist trained for the procedure (TKS).26,27 On average, 
each patient had 12 ablations of 2- minute duration carried out, and 
the minimum number of complete ablations per side was ≥ 4, as rec-
ommended. Patients were hospitalized overnight and followed with 
self- administered BP measurements at home according to written 
instructions.
2.3  |  Measurements
Fasting blood samples were drawn at each visit. Serum creati-
nine was measured with enzymatic method that has been stand-
ardized against isotope dilution mass spectroscopy (CREA Plus, 
Roche Diagnostics, GmbH, Mannheim, Germany), and we calcu-
lated the eGFR based on creatinine (eGFRcrea) using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD- EPI) Equation28 
Cystatin C was measured with standardized particle enhanced tur-
bidimetric immunoassay from Gentian (Moss, Norway) at baseline 
and after six months, whereas a corresponding assay from Roche 
(Basel, Switzerland) was used at the same Cobas 8000- system at 
the 2 years’ follow- up. Both methods were traceable to certified 
reference material, and agreement between the methods was good. 
Cystatin C based eGFR (eGFRcys), and eGFR calculated using a com-
bination of creatinine and cystatin C (eGFRcreacys), were calculated 
according to the respective CKD- EPI Equation23
On a separate day, iohexol clearance was measured as previ-
ously described.24 After an overnight fast, but with instructions 
not to restrict water intake, the patients had five milliliters of io-
hexol (Omnipaque 300 mg I/ml) administered through a periph-
eral venous catheter placed in an antecubital vein. The syringe 
was weighed before and after administration, and the catheter 
was flushed with 30 ml of isotonic saline. The blood sample for 
iohexol concentration measurement was drawn through the same 
catheter. After injection of iohexol, the participants were given a 
light breakfast. The optimal time for sampling was calculated by 
Jacobsson's method, using creatinine- based eGFR.29 The exact 
time in minutes from injection to sampling was measured with a 
separate stopwatch for each person. Serum iohexol concentra-
tion was measured by HPLC, as described.30 mGFR was calculated 
using the equation described by Jacobsson29 and normalized to 
the surface area 1.73 m2.31
At baseline and after six months, each participant delivered two 
separate morning urine samples, whereas only one morning urine 
specimen was requested at the visit two years after RDN. Albumin 
and creatinine concentrations were analyzed in fresh urine sam-
ples. A sample from each specimen was frozen and stored at −20°C 
until 2016, when all samples were analyzed for the tubular damage 
biomarker NAG. Urine albumin- creatinine ratio (ACR; in mg/mmol) 
and NAG- creatinine ratio (NAG- CR; in IU/g) were calculated for all 
specimens.
The study nurses measured height and weight, and body mass 
index (BMI) was calculated. Information about lifestyle was assessed 
by a self- administered questionnaire. Medical history was taken by 
one of the study physicians (AM, JVN).
2.4  |  Statistical analyses
Data are given as mean (±SD), median (interquartile range [IQR]), 
or number (percentage) as appropriate. Within- subject changes in 
normally distributed continuous variables from baseline to follow-
 up after six months and two years were checked with one- way 
repeated- measures ANOVA. The p- value for within- subject simple 
contrasts between baseline and 2 years’ follow- up was assessed. 
To evaluate predictors of 2- year change in kidney function by vari-
ous methods of measurement, as well as 2- year change in the uri-
nary biomarkers, we used multivariable linear regression models. 
Independent variables were baseline age, simultaneous change 
in ambulatory systolic BP, baseline urinary ACR and/or NAG- CR, 
and baseline kidney function and/or urinary biomarker assessed 
in the same way as the dependent variable in the same model. 
Related samples Friedman's two- way analysis of variance by ranks 
with Bonferroni correction for multiple tests were done to test 
for change over time in urinary ACR and NAG- CR, which were not 
normally distributed. A two- sided p- value of < .05 was consid-
ered statistically significant. Analyses were done using IBM SPSS 
Statistics software version 24 and 25 (IBM Corporation, Armonk, 
New York).
3  |  RESULTS
3.1  |  Cohort characteristics
Within four weeks after a baseline visit, bilateral RDN was ac-
complished in 23 patients (4 women, 19 men; mean (SD) age 54 
(±9) years), with no periprocedural complications, as described.26 
All patients underwent the 6 months’ follow- up visit, whereas one 
woman and two men did not attend the final visit after two years. 
Patient characteristics at baseline and after six months and two 
years for the 20 patients who completed the study are displayed 
in Table 1. Two patients reported current smoking, and seven were 
previous smokers. Mean BMI was in the obesity range. From base-
line to the 2 years’ follow- up, visit, mean ambulatory diastolic BP fell 
significantly, the corresponding systolic BP showed an insignificant 
trend toward a decrease, and the median number of BP- lowering 
drugs decreased slightly. However, a rising trend in all BP measure-
ments was observed between the visits at 6 months and 2 years. 
Controlled BP was observed in eight patients at the 6 months’ and 
only two patients at the 2 years’ follow- up. At least one renin- 
angiotensin- aldosterone system inhibitor (RAASi) was prescribed 
to all participants at all visits, apart from one participant, who had 
discontinued this drug before the 2 years’ follow- up.
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3.2  |  Measurements of kidney function
Creatinine values were stable, whereas cystatin C increased sig-
nificantly from baseline to the 2 years’ follow- up visit (Table 2). At 
baseline, kidney function assessment with mGFR and eGFRcrea gave 
similar values, whereas the mean estimate based on cystatin C nu-
merically was lower. However, after six months mGFR tended to 
decrease (P =.07), whereas both GFR estimates that included cys-
tatin C increased significantly (P =.03 for both). eGFRcrea remained 
practically unchanged (P =.28). After two years, only eGFRcrecys 
was significantly different from the baseline value (80.1 (±19.7) ml/
min/1.73 m2 vs. 76.4 ± 21.5 ml/min/1.73 m2; P =.04), whereas the 
other GFR measures were non- significantly lower than their baseline 
value (Table 2 and Figure 1). One- way repeated- measures ANOVA 
revealed overall significant changes in all estimates of GFR, but not 
mGFR (Table 2).
3.3  |  Predictors of change in kidney function
In multivariable linear regression models, we examined predictors 
of change in measured and estimated GFR; the results are given in 
Table 3. We found that higher baseline age predicted a larger de-
crease in mGFR, whereas age was not associated with change in 
creatinine or cystatin C based eGFR. However, change in ambula-
tory systolic BP was positively associated with a change in eGFRcrea. 
Higher urinary ACR was a borderline significant predictor of eGFR 
decrease in estimates based on cystatin C only. NAG- CR did not 
significantly predict GFR change, neither in models where NAG- CR 
was the only urinary biomarker (Table 3), nor in models which also 
included ACR (data not shown).
3.4  |  Urinary biomarkers of kidney damage
During the first six months after RDN, median (IQR) urinary ACR de-
creased slightly, but not significantly (from 0.73 (0.11– 4.15) mg/mmol 
to 0.64 (0.02– 1.48) mg/mmol; P =.3). The ACR value had increased 
significantly at the 2 years’ follow- up, when median (IQR) was 2.40 
(0.48– 5.56) mg/mmol (P =.014 for difference between six months and 
two years). However, when comparing the baseline ACR with the value 
after two years, no significant change was found (P =.7) (Figure 2).
NAG- CR, a biomarker of tubular dysfunction and damage, in-
creased from baseline (0.84 (0.49– 1.99) IU/g) to the 2 years’ fol-
low- up (2.04 (1.19– 4.12) IU/g). At 6 months’ follow- up, the median 
(IQR) value was (1.55 (0.62– 2.41) IU/g). A non- parametric repeated- 
measures test with Bonferroni correction for multiple comparisons 
yielded a significant overall change with a P- value of .047, whereas 
TA B L E  1  Characteristics at baseline and follow- up (n = 20). The ReShape CV- Risk Study
Baseline
6 months' 
follow- up 2 years' follow- up
P for within- subject 
contrasts between 




Female sex, n (%) 3 (15)
Age, years 54 (±9)
Body mass index, kg/m2 31.9 (±4.8) 32.0 (±5.1) 32.0 (±5.1) .08 .07
Glycosylated hemoglobin, % 5.6 (±0.3) 5.6 (±0.3) 5.6 (±0.4) .7 .3
Total cholesterol, mmol/l 5.1 (±1.2) 5.0 (±0.9) 5.0 (±1.0) .8 .9
LDL cholesterol, mmol/l 3.6 (±1.1) 3.4 (±1.0) 3.4 (±1.0) .1 .2
Office SBP, mm Hg 164 (±21) 139 (±19) 151 (±18) .1 .006
Office DBP, mm Hg 108 (±20) 89 (±13) 97 (±13) .06 .005
Mean ambulatory SBP, mm Hg 156 (±21) 145 (±14) 147 (±14) .09 .06
Mean ambulatory DBP, mm Hg 97 (±14) 89 (±11) 90 (±11) .04 .007
No. of BP lowering drugs 4.5 (4- 8) 4.0 (2- 6) 4.0 (0- 7) .07 .07
Type of BP lowering drug, n (%)
Calcium channel blocker 17 (85) 17 (85) 17 (85)
ACE inhibitor or ARB 20 (100) 20 (100) 19 (95)
Thiazide diuretic 8 (40) 8 (40) 8 (40)
Loop diuretc 14 (70) 13 (65) 11 (55)
Beta blocker 15 (75) 15 (75) 15 (75)
Mineralcorticoid receptor 
blocker
10 (50) 6 (30) 8 (40)
Other 10 (50) 7 (35) 8 (40)
Note: Data are mean (±SD), apart from No. of BP lowering drugs, which are median (min- max).
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; DBP, diastolic blood pressure; LDL, low density 
lipoprotein; SBP, systolic blood pressure.
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pairwise comparisons only showed a significant change between six 
months and two years (P =.049) (Figure 2).
In multivariable linear regression models similar to those used for 
2- year change in GFR, we could not identify any significant predictor 
for 2- year change in ACR or NAG- CR.
4  |  DISCUSSION
In a non- randomized study involving 20 non- diabetic patients with 
TRHT, undergoing bilateral RDN, we studied changes in kidney func-
tion over two years assessed by different methods. We found a dis-
crepancy in the trajectories of measured and various estimates of GFR 
after RDN, especially after six months, with the mean values shifting 
into opposite directions. Also, whereas mGFR and creatinine- based 
estimates of GFR were stable, eGFR based upon the combination of 
creatinine and cystatin C decreased significantly over the 2- year ob-
servational period. Predictors of GFR change varied with the method 
used for GFR assessment. Moreover, we found that whereas albumi-
nuria measured as morning spot urine ACR was relatively unchanged, 
a biomarker of tubular dysfunction, NAG- CR, increased to a statisti-
cally significantly higher value after two years of follow- up.
Previously published studies in humans have concluded that 
RDN is generally safe in terms of kidney structure and function as-
sessed as eGFR, both in the short and long term.12,16,19,32 However, 
our study on patients with TRHT and relatively well- preserved kid-
ney function at baseline suggests that a clinically significant GFR de-
cline may occur. This is in line with the results of a recently published 
Swiss study, where an even more pronounced mGFR decline was 
found one year after RDN in 13 patients with age and BMI compa-
rable to those of the present study, but with slightly lower baseline 
mGFR.25 In general middle- aged populations, mean annual GFR de-
cline is typically around 1 ml/min/1.73 m2,33 whereas our study and 
the Swiss study denote a 2.5 and 12 times more rapid decline rate, 
respectively, in patients with TRHT undergoing RDN. Whether GFR 
change rate after RDN is associated with baseline GFR may be a clin-
ically relevant question that remains to be answered in controlled 
studies.
In the so far largest meta- analysis studying kidney function 
after RDN, including 2550 patients from 56 cohorts, with a mean 
follow- up of 9 months, a funnel plot of eGFR change after RDN 
showed a significant asymmetry. In a few small studies, eGFR fell sig-
nificantly; the opposite was found in a comparable number of stud-
ies, whereas kidney function displayed no significant change in the 
TA B L E  2  Measurements of kidney function at baseline and follow- up (n = 20). The ReShape CV- Risk Study
Baseline
6 months' 
follow- up 2 years' follow- up
P for within- subject contrasts 




Creatinine, µmol/L 90.1 (±23.6) 85.0 (±23.5) 91.3 (±26.1) .62 .025
Cystatin C, mg/L 01.jun (±0.23) 1.00 (±0.25) 01.des (±0.24) .04 <.001
Measured GFR, ml/
min/1.73 m2
83.0 (±20.1) 75.6 (±21.6) 78.2 (±27.6) .38 .24
Estimated GFRcrea, ml/
min/1.73 m2
84.4 (±19.1) 86.7 (±20.2) 81.2 (±21.9) .09 .026
Estimated GFRcys, ml/
min/1.73 m2
76.4 (±21.5) 83.1 (±22.7) 71.9 (±20.3) .09 <.001
Estimated GFRcreacys, ml/
min/1.73 m2
80.1 (±20.0) 85.5 (±22.0) 76.4 (±21.2) .04 <.001
Note: Data are mean (±SD). GFR: Glomerular filtration rate. Estimated GFRcrea, GFRcys and GFRcreacys refer to GFR estimates calculated with the CKD- 
EPI equations based on creatinine, cystatin C and creatinine + cystatin C, respectively.
F I G U R E  1  Mean glomerular filtration 
rate (GFR) by exact measurement (mGFR) 
and three different estimates (eGFRcre, 
eGFRcys, and eGFRcrecys) at baseline, and 
at six months and two years after renal 
denervation
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majority of studies.32 Although the conclusion that RDN generally 
does not infer damage to the kidney function is the most important 
result of this meta- analysis, the asymmetry may serve as a reminder 
that kidney function should be evaluated carefully in each clinical 
setting. Most patients treated with RDN have had TRHT for years, 
and other risk factors such as obesity and the metabolic syndrome, 
as well as early end- organ damage, are prevalent. Therefore, their 
age- related GFR decline rate is expected to be elevated compared 
to normotensive persons.34,35 Their autoregulation is often blunted, 
and these patients are vulnerable to changes in GFR related to alter-
ation in BP and antihypertensive medication. This should all be taken 
into account when evaluating GFR change after RDN and similar in-
vasive procedures, both in research and in clinical settings. The pres-
ent study adds further knowledge to this obstacle by showing that 
different measurements to evaluate GFR, taken at the same time 
point, may show diverging result, supporting the need for repeated 
measurements and careful evaluation of the situation before a con-
clusion can be made.
Several articles including a recent meta- analysis have reported 
a significant or near- significant increase in serum cystatin C levels 
the first year after RDN,32,36,37 in spite of stable creatinine values 
and eGFRcrea. Cystatin C is less influenced by non- renal factors than 
creatinine, and eGFRcys is suggested to serve as a confirmatory test 
when eGFRcre is presumed to deviate from true GFR due to abnor-
mally high or low muscle mass.38 However, although cystatin C is 
not affected by muscle mass, levels are increased with inflamma-
tion, glucocorticoid use, hyperthyroidism, and obesity.24,38 Possibly, 
cystatin C may reflect chronic inflammation in TRHT patients, who, 
similar to the participants of the present study, frequently are over-
weight or obese.
GFR measured with iohexol clearance or other gold- standard 
methods are cumbersome and not feasible in regular clinical prac-
tice. However, since the reason for the apparent discrepant GFR 
estimates found in our study is unknown, and since long- term renal 
consequences of RDN have not been studied using gold- standard 
methods, larger randomized controlled studies of RDN applying 
mGFR as well as various eGFR equations over time should be ac-
complished. Thus, clinicians may be advised how to interpret various 
eGFR values over the time course after RDN.
We tested potential predictors for change in GFR measured 
by the various methods. High age was associated with decrease in 
mGFR, but not eGFR, whereas change in systolic BP was positively 
associated with change in eGFRcrea. These results should be inter-
preted with caution, particularly due to the small number of individ-
uals in our study. That baseline eGFRcys predicted decrease in the 
same variable may suggest that our findings to some extent have 
been influenced by regression toward the mean.
Several studies have shown a decrease in albuminuria after 
RDN,20,32,39 probably mainly related to a fall in BP and an attenuated 
renin- angiotensin- aldosterone system (RAAS) activity secondary 
to blunted sympathetic nerve system activity. Possibly related to 
diabetes being an exclusion criterion in our study, median baseline 
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effectively lowers urinary albumin excretion. Numerically, median 
ACR was higher after two years, but the difference from baseline 
was not significant, and the value was still below the lower limit for 
the albuminuria range previously classified as microalbuminuria. A 
concurrent trend toward a slightly higher BP was also observed, 
making the cause and effect of these minor changes difficult to 
interpret. However, the slight, but statistically significant increase 
in NAG- CR, a biomarker of tubular damage, is of interest. We have 
previously published that NAG- CR was an independent predic-
tor of myocardial infarction in the general population,40 but so far, 
data confirming an independent association between NAG- CR and 
kidney function decline are lacking.41 Tubular biomarkers have, to 
our knowledge, never previously been studied in RDN treated pa-
tients. Renal tubular cells have obvious important functions in BP 
regulation, as they execute renal salt handling and are essential in 
tubuloglomerular feedback loops. Thus, the close interplay between 
the sympathetic nerve system and the RAAS also involves tubular 
cell functions. Similar to our study, an increase in NAG excretion 
was found six months after RDN in a sham- controlled experimen-
tal study in dogs.42 Also, less tubular damage, but more interstitial 
edema in inflammatory infiltrate, was seen in renal biopsies in RDN 
treated dogs compared to the sham- treated animals, suggesting that 
long- term renal effects of RDN should be studied further. In this re-
gard, urinary tubular biomarkers may be of interest. In a large cohort 
of patients with hypertension and CKD, different markers of tubular 
cell health independently predicted cardiovascular outcome.43 In 
the present study, the lack of control group prevented us from com-
paring increases in NAG- CR due to disease to changes inferred by 
the treatment method.
The small study size and lack of control group are obvious lim-
itations that apply to our study. However, the careful selection 
of patients and stringent criteria to enter the study, including the 
investigator- observed drug intake and use of 24- hour ambulatory 
BP measurements, as well as gold- standard measurements of GFR, 
are important strengths.
In summary, in a small study of patients treated for true TRHT 
by complete bilateral RDN, we found that various measurements 
and estimates of GFR after six months and two years showed di-
verging results, suggesting that evaluation of kidney function after 
this procedure should be done with care. Our findings denote that 
a clinically significant GFR decline after RDN cannot be precluded, 
and future studies applying gold- standard GFR measurements in 
RDN patients and controls are needed. Moreover, the finding of sig-
nificantly increasing values of urinary NAG- CR, a biomarker of renal 
tubular function, suggests that long- term follow- up of kidney func-
tion should be done, to investigate whether early structural damage 
eventually may have clinical consequences.
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